{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:43Z","timestamp":1791920923521,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the key medical research projects of Hainan Health Department","award":["2010-19"],"award-info":[{"award-number":["2010-19"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00280-016-3136-1","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T14:22:13Z","timestamp":1472134933000},"page":"801-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"78","author":[{"given":"Jiangzheng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanda","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"issue":"14","key":"3136_CR1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med 328(14):1002\u20131006","journal-title":"N Engl J Med"},{"issue":"4","key":"3136_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/07357900701788098","volume":"26","author":"H Abali","year":"2008","unstructured":"Abali H, Urun Y, Oksuzoglu B et al (2008) Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 26(4):401\u2013406","journal-title":"Cancer Invest"},{"issue":"3","key":"3136_CR3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3904\/kjim.2006.21.3.159","volume":"21","author":"SH Park","year":"2006","unstructured":"Park SH, Kim S, Ko OB et al (2006) ESHAP salvage therapy for refractory and relapsed non-Hodgkin\u2019s lymphoma: a single center experience. Korean J Intern Med 21(3):159\u2013164","journal-title":"Korean J Intern Med"},{"issue":"4","key":"3136_CR4","first-page":"389","volume":"22","author":"HQ Huang","year":"2003","unstructured":"Huang HQ, Jiang WQ, Wang W et al (2003) Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin\u2019s lymphoma treated by EPOCH regimen. Ai Zheng 22(4):389\u2013392","journal-title":"Ai Zheng"},{"issue":"2","key":"3136_CR5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0609.2006.00796.x","volume":"78","author":"P Schutt","year":"2007","unstructured":"Schutt P, Passon J, Ebeling P et al (2007) Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol 78(2):93\u2013101","journal-title":"Eur J Haematol"},{"issue":"12","key":"3136_CR6","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","volume":"118","author":"G Visani","year":"2011","unstructured":"Visani G, Malerba L, Stefani PM et al (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients. Blood 118(12):3419\u20133425","journal-title":"Blood"},{"issue":"7","key":"3136_CR7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","volume":"11","author":"N Andre","year":"2014","unstructured":"Andre N, Carre M, Pasquier E (2014) Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11(7):413\u2013431","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3136_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1658-3876(10)50051-7","volume":"3","author":"NA Bary El","year":"2010","unstructured":"El Bary NA, Hashem T, Metwally H et al (2010) A phase II study of high-dose celecoxib and metronomic \u2018low-dose\u2019 cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma. Hematol Oncol Stem Cell Ther 3(1):13\u201318","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"10","key":"3136_CR9","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.23422","volume":"112","author":"M Coleman","year":"2008","unstructured":"Coleman M, Martin P, Ruan J et al (2008) Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 112(10):2228\u20132232","journal-title":"Cancer"},{"issue":"11","key":"3136_CR10","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","volume":"116","author":"J Ruan","year":"2010","unstructured":"Ruan J, Martin P, Coleman M et al (2010) Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 116(11):2655\u20132664","journal-title":"Cancer"},{"issue":"7","key":"3136_CR11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2014.03.022","volume":"38","author":"R Buckstein","year":"2014","unstructured":"Buckstein R, Kerbel R, Cheung M et al (2014) Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leuk Res 38(7):756\u2013763","journal-title":"Leuk Res"},{"issue":"10","key":"3136_CR12","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1158\/0008-5472.CAN-13-2044","volume":"74","author":"R Mehran","year":"2014","unstructured":"Mehran R, Nilsson M, Khajavi M et al (2014) Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res 74(10):2731\u20132741","journal-title":"Cancer Res"},{"issue":"2","key":"3136_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/02656736.2015.1099168","volume":"32","author":"Z WangYuan","year":"2016","unstructured":"WangYuan Z, JiangZheng Z, Lu YD et al (2016) Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma. Int J Hyperth 32(2):193\u2013198","journal-title":"Int J Hyperth"},{"issue":"2","key":"3136_CR14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2005-11-4570","volume":"108","author":"P Mancuso","year":"2006","unstructured":"Mancuso P, Colleoni M, Calleri A et al (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2):452\u2013459","journal-title":"Blood"},{"issue":"3","key":"3136_CR15","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12032-014-0872-0","volume":"31","author":"S Elsamany","year":"2014","unstructured":"Elsamany S, Farooq MU, Elsirafy M et al (2014) Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression. Med Oncol 31(3):872","journal-title":"Med Oncol"},{"issue":"2","key":"3136_CR16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-014-2492-y","volume":"74","author":"N Masuda","year":"2014","unstructured":"Masuda N, Higaki K, Takano T et al (2014) A phase II study of metronomic paclitaxel\/cyclophosphamide\/capecitabine followed by 5-fluorouracil\/epirubicin\/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing\/HER2-negative primary breast cancer. Cancer Chemother Pharmacol 74(2):229\u2013238","journal-title":"Cancer Chemother Pharmacol"},{"issue":"27","key":"3136_CR17","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184\u20134190","journal-title":"J Clin Oncol"},{"issue":"3","key":"3136_CR18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","volume":"20","author":"J Ruan","year":"2009","unstructured":"Ruan J, Hajjar K, Rafii S et al (2009) Angiogenesis and antiangiogenic therapy in non-Hodgkin\u2019s lymphoma. Ann Oncol 20(3):413\u2013424","journal-title":"Ann Oncol"},{"issue":"3","key":"3136_CR19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1593\/neo.121962","volume":"15","author":"D Ribatti","year":"2013","unstructured":"Ribatti D, Nico B, Ranieri G et al (2013) The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 15(3):231\u2013238","journal-title":"Neoplasia"},{"issue":"12","key":"3136_CR20","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","volume":"96","author":"P Salven","year":"2000","unstructured":"Salven P, Orpana A, Teerenhovi L et al (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96(12):3712\u20133718","journal-title":"Blood"},{"issue":"2","key":"3136_CR21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1034\/j.1600-0609.2002.01609.x","volume":"68","author":"N Niitsu","year":"2002","unstructured":"Niitsu N, Okamato M, Nakamine H et al (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin\u2019s lymphoma. Eur J Haematol 68(2):91\u2013100","journal-title":"Eur J Haematol"},{"issue":"1","key":"3136_CR22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4274\/tjh.2013.0325","volume":"32","author":"H UskudarTeke","year":"2015","unstructured":"UskudarTeke H, Gunduz E, Akay OM et al (2015) Are the high serum interleukin-6 and vascular endothelial growth factor levels useful prognostic markers in aggressive non-hodgkin lymphoma patients? Turk J Haematol 32(1):21\u201328","journal-title":"Turk J Haematol"},{"issue":"8","key":"3136_CR23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00277-005-1020-x","volume":"84","author":"LM Pedersen","year":"2005","unstructured":"Pedersen LM, Klausen TW, Davidsen UH et al (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin\u2019s lymphoma. Ann Hematol 84(8):510\u2013516","journal-title":"Ann Hematol"},{"issue":"11","key":"3136_CR24","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","volume":"7","author":"D Lyden","year":"2001","unstructured":"Lyden D, Hattori K, Dias S et al (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7(11):1194\u20131201","journal-title":"Nat Med"},{"issue":"4","key":"3136_CR25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3324\/haematol.10723","volume":"92","author":"C Igreja","year":"2007","unstructured":"Igreja C, Courinha M, Cachaco AS et al (2007) Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica 92(4):469\u2013477","journal-title":"Haematologica"},{"issue":"9","key":"3136_CR26","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2174\/156800911798073014","volume":"11","author":"J Ruan","year":"2011","unstructured":"Ruan J (2011) Antiangiogenic therapies in non-Hodgkin\u2019s lymphoma. Curr Cancer Drug Targets 11(9):1030\u20131043","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"3136_CR27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423\u2013436","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"3136_CR28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/apm.12201","volume":"122","author":"K Norrby","year":"2014","unstructured":"Norrby K (2014) Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth? APMIS 122(7):565\u2013579","journal-title":"APMIS"},{"issue":"2","key":"3136_CR29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10456-012-9321-x","volume":"16","author":"E Pasquier","year":"2013","unstructured":"Pasquier E, Tuset MP, Street J et al (2013) Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis 16(2):373\u2013386","journal-title":"Angiogenesis"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3136-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:24:27Z","timestamp":1601043867000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3136-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["3136"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3136-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}